Suprachoroidal Space TA Formulation Advances in Clinical Trials

 

A proprietary form of triamcinolone acetonide for injection into the suprachoroidal space (CLA-TA; Clearside Biomedical) for the treatment of noninfectious uveitis met primary and secondary endpoints in the Dogwood clinical trial, according to a company press release of top-line data. Clearside also announced updates on the enrollment status of the Peachtree and Tanzanite trials, both of which will assess the safety and efficacy of CLA-TA in ocular diseases.

In the Dogwood trial, a single suprachoroidal microinjection of CLA-TA resulted in reduction of central subfield thickness (P = .0018) and mean improvement from baseline in BCVA (P = .0004) at 8 weeks. There were no serious adverse events related to the treatment in the trial, including no increases in IOP.

The Peachtree trial, a phase 3 trial assessing CLA-TA in the suprachoroidal space for the treatment of macular edema associated with noninfectious uveitis, has enrolled its first patient. The Tanzanite trial, a phase 2 clinical trial assessing the safety and efficacy of CLS-TA in the suprachoroidal space combined with intravitreal aflibercept (Eylea, Regeneron) for treatment of macular edema associated with retinal vein occlusion, has completed enrollment.

 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Karen Roman
Editor-in-Chief
484-581-1827
kroman@bmctoday.com

Janet Burk
Publisher
214-394-3551
jburk@bmctoday.com

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.